Composition and method for treating age-related disorders

Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Embryonic structure

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S283100, C424S450000, C424S465000

Reexamination Certificate

active

07033612

ABSTRACT:
There is provided a composition for the prevention and treatment of age-related physical and mental disorders that includes phospholipids that have been extracted from chick embryos aged between about 6 days old and about 14 days old. Also provided is a method for extracting these phospholipids by incubating them for between about 6 days to about 14 days. The chick embryos are then prepared for chemical extraction, and the lipids are extracted from the chick embryos. Further provided is a method for preventing and treating age-related physical and mental disorders, in human subjects in need thereof, by administering a sufficient dosage of a composition including phospholipids extracted from chick embryos incubated for between about 6 days and about 14 days to a human subject.

REFERENCES:
patent: 5484611 (1996-01-01), Noble
patent: 5780615 (1998-07-01), Bucala et al.
patent: 5801200 (1998-09-01), Bucala et al.
patent: 6300377 (2001-10-01), Chopra
patent: 6500843 (2002-12-01), Steiner et al.
patent: 6514973 (2003-02-01), Buchholz et al.
patent: 2004/0234544 (2004-11-01), Jager et al.
patent: 2004/0234587 (2004-11-01), Sampalis
patent: 0 437 334 (1995-08-01), None
R. Franson et al,Solubilization and Characterization of a Neutral- Active, Calcium-Dependant, Phosholipase A2from Rabbit Heart and Isolated Chick Embryo Myocytes, J. Mol. Cell Cardiol. 15: 189-196 (1983).
M. Mehlman et al,Studies on the Distribution of Free Camitine and the Occurrence and Nature of Bound Camitine, Arch. Biochem. Biophys. 98: 146-153 (1962).
F. Granata et al,Phosphocholine and phosphoethanolamine During Chick Embryo Myogenesis: a31P-NMR Study, Biochem. Biophys. Acta 1483: 334-342 (2000).
L. Allen et al,Partial Phenotypic Suppression of a Peroxisome-deficient Animal Cell Mutant Treated with Aminoglycoside G418, J. Biol. Chem. 267: 13191-13199 (1992).
G. Arthur et al,The Distribution and Acyl Composition of Plasmalogens in Guinea Pig Heart, Lipids 20:693-698 (1985).
J. Brook et al,Dietary Soya Lecithin Decreases Plasma Triglyceride Levels and Inhibits Collagen- and ADP-Induced Platelet Aggregation, Biochem. Med. Metab. Biol. 35:31-39 (1986).
I. Carrie et al,Phospholipid Supplementation Reverses Behavioral and Biochemical Alterations Induced by N-3 Polyunsaturated Fatty Acid Deficiency in Mice, J. Lipid Res. 41:473-480 (2000).
X. Chen et al,Potassium Flux through Gramicidin Ion Channels is Augmented in Vesicles Comprised of Plasmenylcholine: Correlations between Gramicidin Conformation and Function in Chemically Distinct Host Bilayer Matrices, Biochemistry 34:7356-7364 (1995).
K. Chepenik et al,On the Presence of Plasmologens in Developing Rat Embryos, Int. J. Biochem. 11:605-607 (1980).
I. Delton-Vandenbroucke et al,Dual Regulation of Glutathione Peroxidase by Docosahexaenoic Acid in Endothelial Cells Depending on Concentration and Vascular Bed Origin, Free Radical Biol. Med. 30:895-904 (2001).
A. Diagne et al,Studies of Ether Phospholipids. II Comparative composition of various tissues from human, rat and guinea pig, Biochim. Biophys Acta 793:221-231 (1984).
J. Duhm et al,Accelerated Maximal Velcoity of the Red Blood Cell Na+/K+Pump in Hyperlipidemia is Related to Increase in 1-palmitoyl,2-arachidonoyl-plasmalogen Phosphatidylethanolamine, Biochim. Biophys. Acta 1149:185-188 (1993).
B. Engelmann et al,Plasmalogen Phospholipids as Potential Protectors against Lipid Peroxidation of Low Density Lipoproteins, Biochem. Biophys. Res. Commun. 204:1235-1242 (1994).
H. Goldfine et al,Phase Behavior of Ether Lipids from Clostridium Butyricum, Biochemistry 20:2908-2916 (1981).
H. Goldfine et al,Lipid Shape as a Determinant of Lipid Composition in Clostridium Butyricum: The Effects of Incorporation of Various Fatty Acids on the Ratios of the Major Ether Lipids, Biochim. Biophys. Acta 904:283-289 (1987).
M. Hack et al,On the Plasmalogenation of Myocardial Choline Glycerophospholipid During Maturation of Various Vertebrates, Comp. Biochem. Physiol. 89B:111-118 (1988).
S. Hazen et al,Activation of a Membrane-Associated Phospholipase A2during Rabbit Myocardial Ischemia Which is Highly Selective for Plasmologen Substrate, J. Biol. Chem. 266:5629-5633 (1991).
S. Hazen et al,Purification and Characterization of Canine Myocardial Cytosolic Phospholipase A2A calcium-independent phospholipase with absolute f1-2 regiospecificity for diradyl glycerophospholipids, J. Biol. Chem. 265:10622-10630 (1990).
N. Khaselev et al,Susceptibility of Plasmenyl Glycerophosphoethanolamine Lipids Containing Arachidonate to Oxidative Degradation, Free Radical Biol. Med. 26:275-284 (1999).
M. Lee et al,Phospholipid Functional Groups Involved in Protein Kinase C Activation, Phorbol Ester Binding and Binding to Mixed Micelles, J. Biol. Chem. 264:14797-14805 (1989).
M. Lee et al,Supplementation of the Phosphatidyl-L-serine Requirement of Protein Kinase C with Nonactivating Phospholipids, Biochemistry 31:5176-5182 (1992).
K. Lohner et al,Phase Behavior of Ethanolamine Plasmalogen, Chem. Phys. Lipids 34:163-170 (1984).
A. Maldjian et al,The Transfer of Docosahexaenoic Acid from the Yolk to the Tissues of the Chick Embryo, Biochim. Biophys. Acta 1258:81-89 (1995).
M. Martinez,Docosahexaenoic Acid Therapy in Docosahexaenoic Acid-Deficient Patients with Disorders of Peroxisomal Biogenesis, Lipids 31:S145-S152 (1996).
M. Martinez et al,Therapeutic Effects of Docosahexaenoic Acid Ethyl Ester in Patient with Generalized Peroxisomal Disorders, Am. J. Clin. Nutr. 71:376S-285S (2000).
N. Maulik et al,Fatty Acid Profiles of Plasmalogen Choline and Ethanolamine Glycerophospholipids in Pig and Rat Hearts, J. Pharmaceut. Biomed. Analysis 14: 49-56 (1995).
Y. Nakagawa et al,Changes in the Composition of Fatty Chains of Diacyl, Alkylacyl and Alkenylacyl Ethanolamine and Choline Phosphoglycerides During the Development of Chick Heart Ventricular Cells, Biochim. Biophys. Acta 712:667-676 (1982).
N. Nagan et al,A Fibroblast Cell Line Defective in Alkyl-Dihydroxyacetone Phosphate Synthase: A Novel Defect in Plasmalogen Biosynthesis, Proc. Natl. Acad. Sci. USA 94:4475-4480 (1997).
D. Neel et al,Changes in Phospholipids from Chick Fibroblasts during Embryo Development, Biochem. Biophys. Res. Commun. 98:21-27 (1981).
A. Rizzo et al,Phospholipid Distribution and Fatty Acid Composition in Different Brain Regions during Chick Embryo Development, J. Neurochem. 64: 1728-1733 (1995).
P. Sindelar et al,The Protective Role of Plasmologens in Iron-Induced Lipid Peroxidation, Free Radical Biol. Med. 26: 318-324 (1999).
T. Sugiura et al,Ether Lysophospholipid-induced Production of Platelet-Activating Factor in Human Polymorphonuclear Leukocytes, Biochim. Biophys. Acta 1047:223-232 (1990).
P. Thome et al,Clofibrate and Other Peroxisomal Proliferating Agents Relatively Specifically Inhibit Synthesis of Ethanolamine Phosphoglycerides in Cultured Human Fibroblasts, Biochim. Biophys. Acta 1214:161-170 (1994).
L. Torello et al,A Comparative-Evolutionary Study of Lipids in the Aging Brain of Mice, Neurobiol. Aging 7:337-346 (1986).
Y. Uemura et al,A Coenxyme A-independent Transacylase Is Linked to the Formation of Platelet-Activating Factor(PAF)by Generating the Lyso-PAF Intermediate in the Remodeling Pathway, J. Biol. Chem. 266:8268-8272 (1991).
M. Venable et al,Conversion of 1-O-[3H]Alkyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine to Lyso Platelet-activating Factor by the CoA-independent Transacylase in Membrane Fractions of Human Neutrophils, J. Biol. Chem. 266:18691-18698 (1991).
J. Wojcicki et al,Effects of “Essential” Phospholipids(EPL)on Experimental Ethanol-Induced Cardiomyopathy, Arzneimit. Forsch. (Drug Rs.) 25:1420-1422 (1975).
R. Zoeller et al,A Possible Role for Plasmalogens in Protecting Animal Cells against Photosensitized Killing, J. Biol. Chem. 263:11590-11596 (1988).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Composition and method for treating age-related disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Composition and method for treating age-related disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating age-related disorders will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3560150

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.